Ligelizumab Not Superior to Omalizumab in Chronic Spontaneous Urticaria Trials
Ligelizumab is a high-affinity monoclonal anti-immunoglobulin E antibody.
All articles by Steve Duffy
Keytruda Approved for Adjuvant Treatment IIB, IIC Melanoma Following Resection
Approval was based on data from the phase 3 KEYNOTE-716 trial, which enrolled 976 participants.
Rilzabrutinib Fails in Phase 3 Pemphigus Trial
Rilzabrutinib is an oral Bruton tyrosine kinase inhibitor currently in development for a number of immune-mediated diseases.
MPR Weekly Dose #73: Interview with Dr Joshua Barocas
To get a better understanding of the situation and how the future months could unfold, MPR sat down with Joshua Barocas, MD, an Assistant Professor of Medicine at the Boston University School of Medicine and Infectious Diseases physician at Boston Medical Center.
Generic Version of Foscavir Now Available
Foscarnet sodium injection is indicated to treat cytomegalovirus retinitis in patients with AIDS and acyclovir-resistant mucocutaneous HSV in immunocompromised patients.
Actemra Gains New Indication for Systemic Sclerosis-Associated Interstitial Lung Disease
The FDA has approved Actemra® (tocilizumab; Genentech) subcutaneous injection for slowing the rate of decline in pulmonary function in SSc-ILD.
Novel Rx Device for Sleep Apnea, Snoring Gets FDA Approval
The eXciteOSA device is used while the individual is awake and provides electrical muscle stimulation through a mouthpiece that sits around the tongue.
FDA Identifies Most Needed Meds to Address Urgent Medical Conditions
This action was in response to an executive order issued on August 6, 2020 aimed at protecting the public against outbreaks of emerging diseases and chemical, biological, radiological, and nuclear threats.
NIH: Study Will Identify Most Promising Therapies for COVID-19
So far, the therapies scheduled to be part of the trial are risankizumab, an interleukin-23 antagonist, and lenzilumab, an anti-human granulocyte macrophage-colony stimulating factor monoclonal antibody.
US Cuts Deal With Pfizer, BioNTech for 100 Million COVID-19 Vaccine Doses
The US Department of Health and Human Services and the Department of Defense have agreed to receive 100 million doses of BNT162, a vaccine for SARS-CoV-2, once the manufacturers obtains approval or emergency use authorization (EUA) from the Food and Drug Administration.
- Loading...
Loading...
Next post in Practice Management
Loading... 
Loading...